MENU
+Compare
SPRY
Stock ticker: NASDAQ
AS OF
Nov 19, 04:59 PM (EDT)
Price
$7.10
Change
+$0.01 (+0.14%)
Capitalization
700.84M

SPRY ARS Pharmaceuticals Forecast, Technical & Fundamental Analysis

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis... Show more

SPRY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for SPRY with price predictions
Nov 18, 2025

SPRY's Indicator enters downward trend

The Aroon Indicator for SPRY entered a downward trend on November 18, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 267 similar instances where the Aroon Indicator formed such a pattern. In of the 267 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 16, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on SPRY as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for SPRY turned negative on November 17, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRY advanced for three days, in of 289 cases, the price rose further within the following month. The odds of a continued upward trend are .

SPRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.746) is normal, around the industry mean (23.122). P/E Ratio (151.250) is within average values for comparable stocks, (61.014). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.073). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (5.147) is also within normal values, averaging (332.704).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SPRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
SPRY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

SPRY is expected to report earnings to fall 20.19% to -41 cents per share on March 19

ARS Pharmaceuticals SPRY Stock Earnings Reports
Q4'25
Est.
$-0.41
Q3'25
Missed
by $0.06
Q2'25
Est.
$-0.46
Q1'25
Missed
by $0.01
Q4'24
Beat
by $0.61
The last earnings report on November 10 showed earnings per share of -51 cents, missing the estimate of -46 cents. With 2.50M shares outstanding, the current market capitalization sits at 700.84M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
11682 El Camino Real
Phone
+1 858 771-9307
Employees
26
Web
https://www.ars-pharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FBTIX42.12N/A
N/A
Fidelity Advisor Biotechnology I
RYICX114.72N/A
N/A
Rydex Internet C
GQFIX12.70N/A
N/A
GQG Partners Global Quality Value Fd Ins
SSBIX14.16-0.06
-0.42%
State Street Balanced Index K
PNOPX131.11-1.32
-1.00%
Putnam Sustainable Leaders A

SPRY and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRY has been loosely correlated with LPCN. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRY jumps, then LPCN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRY
1D Price
Change %
SPRY100%
-3.14%
LPCN - SPRY
63%
Loosely correlated
+7.67%
KROS - SPRY
34%
Loosely correlated
+0.98%
DAWN - SPRY
32%
Poorly correlated
-3.17%
ANAB - SPRY
31%
Poorly correlated
+6.44%
REPL - SPRY
31%
Poorly correlated
-0.34%
More